Premium
A human monoclonal antibody against the distal carboxyl terminus of ADAMTS‐13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura
Author(s) -
Halkidis Konstantine,
Siegel Don L.,
Zheng X. Long
Publication year - 2021
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.15332
Subject(s) - adamts , monoclonal antibody , thrombotic thrombocytopenic purpura , autoantibody , thrombospondin , thrombotic microangiopathy , adamts13 , antibody , chemistry , disintegrin , monoclonal , metalloproteinase , recombinant dna , microbiology and biotechnology , biochemistry , medicine , matrix metalloproteinase , immunology , platelet , biology , gene , disease
Background Immune thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy, resulting from a severe deficiency of plasma ADAMTS‐13 (A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motif, member 13) activity. IgG‐type autoantibodies are primarily responsible for the inhibition of plasma ADAMTS‐13 activity. However, the mechanism underlying autoantibody‐mediated inhibition is not fully understood. Objective The purpose of the present study is to determine the role of IgG autoantibodies against various carboxyl‐terminal domains of ADAMTS‐13 in regulating ADAMTS‐13 activity and its inhibition. Method Various human monoclonal antibodies isolated by phage display, recombinant protein expression and purification, and biochemical analyses were employed for the study. Results Our results demonstrate for the first time that a human monoclonal antibody fragment, the single chain fragment of the variable region (scFv) isolated from a patient with acute iTTP that binds the distal carboxyl‐terminus of ADAMTS‐13, is able to activate ADAMTS‐13 and increase the proteolytic cleavage of a FRETS‐VWF73 substrate; moreover, binding of such a human monoclonal antibody against the carboxyl‐terminus of ADAMTS‐13 to plasma ADAMTS‐13 appears to modulate inhibition by another human monoclonal antibody (i.e., scFv4‐20), also isolated from an iTTP patient, that targets the spacer domain of ADAMTS‐13. These results provide new insights into our understanding of the pathogenesis of iTTP.